CG Oncology Inc. Common s...

19.02
-3.22 (-14.48%)
At close: Apr 03, 2025, 11:59 AM

Company Description

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.

Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology Inc. Common stock
CG Oncology Inc. Common stock logo
Country United States
IPO Date n/a
Industry Biotechnology
Sector Healthcare
Employees 113
CEO Arthur Kuan

Contact Details

Address:
No Address available
No city data available, Delaware
United States
Website n/a

Stock Details

Ticker Symbol CGON
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001991792
CUSIP Number 156944100
ISIN Number US1569441009
Employer ID 37-1611499
SIC Code 2836

Key Executives

Name Position
Arthur Kuan Chairman & Chief Executive Officer
Ambaw Bellete M.S. President & Chief Operating Officer
Amy Steele Vice President of Finance, Accounting & Administration
Bing Kung Vice President of Corporate Development
Dr. Vijay Kasturi M.D. Chief Medical Officer
Joshua F. Patterson General Counsel & Chief Compliance Officer
Sarah Connors Vice President of Communications & Patient Advocacy
Swapnil Bhargava Ph.D. Chief Technical Officer

Latest SEC Filings

Date Type Title
Mar 28, 2025 S-3ASR Automatic shelf registration statement of securiti...
Mar 28, 2025 10-K Annual Report
Mar 28, 2025 8-K Current Report
Mar 24, 2025 8-K Current Report
Mar 18, 2025 4 Filing
Feb 19, 2025 4 Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Jan 28, 2025 SCHEDULE 13G/A [Amend] Filing
Jan 14, 2025 4 Filing
Jan 10, 2025 8-K Current Report